Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut feeling: probiotic pill tested as long COVID remedy

NCT ID NCT06643299

Symptom relief Sponsor: Rush University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether taking a probiotic pill daily for four months can reduce Long COVID symptoms and improve quality of life. Researchers will enroll 180 adults with persistent Long COVID symptoms. Half will get the probiotic, half a placebo, and the study will compare how many shift from moderate-to-severe to mild symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
probiotic (BlueBiotics: Ultimate Care)
What this could lead to
If it works, this could point toward a simple, safe daily supplement to reduce Long COVID symptoms and improve quality of life.
What could go wrong
This is a mid-stage trial with only 180 participants, so results may not apply to everyone. Probiotics are generally safe but may not help all Long COVID symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

194 people

The number who actually took part.

Started

May 2025

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years who report Long COVID with persistent symptoms at the time of study initiation Exclusion Criteria: * No longer have symptoms consistent with LC * Are unable to take the study medication daily * Are currently pregnant or planning to become pregnant over the course of the study * Are currently breastfeeding * Have been diagnosed with an immune-compromising condition * Are currently taking immunosuppressants * Do not speak English as a primary language * Are regularly taking probiotics * Are enrolled in another Long COVID study with an intervention

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Post-acute COVID-19 syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

long COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Post-acute COVID-19 syndrome

Contacts and locations

Locations

  • Rush University Medical Center

    Chicago, Illinois, 60612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.